These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18661520)

  • 1. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark.
    Kjaer SK; Breugelmans G; Munk C; Junge J; Watson M; Iftner T
    Int J Cancer; 2008 Oct; 123(8):1864-70. PubMed ID: 18661520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?
    Kjær SK; Munk C; Junge J; Iftner T
    Cancer Causes Control; 2014 Feb; 25(2):179-89. PubMed ID: 24242002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women.
    Nielsen A; Iftner T; Nørgaard M; Munk C; Junge J; Kjaer SK
    Sex Transm Infect; 2012 Dec; 88(8):627-32. PubMed ID: 22773328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
    BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 7. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
    Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
    J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women.
    Hosaka M; Fujita H; Hanley SJ; Sasaki T; Shirakawa Y; Abiko M; Kudo M; Kaneuchi M; Watari H; Kikuchi K; Sakuragi N
    Int J Cancer; 2013 Jan; 132(2):327-34. PubMed ID: 22729477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination.
    Jalilvand S; Shoja Z; Nourijelyani K; Tohidi HR; Hamkar R
    J Med Virol; 2015 Feb; 87(2):287-95. PubMed ID: 25156655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
    Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
    Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
    Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
    Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
    Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.
    Konno R; Tamura S; Dobbelaere K; Yoshikawa H
    Cancer Sci; 2011 Apr; 102(4):877-82. PubMed ID: 21251162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
    Falcaro M; Soldan K; Ndlela B; Sasieni P
    BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
    Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
    Pérez-Castro S; Lorenzo-Mahía Y; Iñarrea Fernández A; Lamas-González MJ; Sarán-Díez MT; Rubio-Alarcón J; Reboredo-Reboredo MC; Mosteiro-Lobato S; López-Miragaya I; Torres-Piñón J; Melón-García S
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):479-85. PubMed ID: 24274937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.